Mohammad Rahnavardi1, Jaime Santibanez, Karan Sian, Tristan D Yan. 1. The Collaborative Research (CORE) Group, Sydney, Australia; ; Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia; ; The Baird Institute for Applied Heart and Lung Surgical Research, Sydney, Australia;
Abstract
BACKGROUND: Transcatheter aortic valve implantation (TAVI) through a transapical approach (TAAVI) for severe aortic stenosis becomes the procedure of choice in cases where patients have peripheral artery disease and unfeasible access due to excessive atherosclerotic disease of the iliofemoral vessels and aorta. The present systematic review aimed to assess the safety, success rate, clinical outcomes, hemodynamic outcomes, and survival benefits of TAAVI. METHODS: Electronic searches were performed in 6 databases from January 2000 to February 2012. The primary end points included feasibility and safety. Other end points included echocardiographic findings, functional class improvement, and survival. RESULTS: After applying the inclusion and exclusion criteria, 48 out of 154 shortlisted potentially relevant articles were selected for assessment. Of these, 26 studies from 24 centers including total number of 2,807 patients were included for appraisal and data extraction. The current evidence on TAAVI for aortic stenosis is limited to observational studies. Successful TAAVI implantation occurred in >90% of patients. On average, the procedure took between 64 to 154 minutes to complete. The incidence of major adverse events included 30-day mortality (4.7-20.8%); cerebrovascular accident (0-16.3%); major tachyarrhythmia (0-48.8%); bradyarrhythmia requiring permanent pacemaker insertion (0-18.7%); cardiac tamponade (0-11%); major bleeding (1-17%); myocardial infarction (0-6%); aortic dissection/rupture (0-5%); moderate to severe paravalvular leak (0.7-24%); cardiopulmonary bypass support (0-15%); conversion to surgery (0-9.5%); and valve-in-valve implantation (0.6-8%). Mean aortic valve area improved from 0.4-0.7 cm(2) before TAAVI to 1.4-2.1 cm(2) after TAAVI. The peak pressure gradient across the aortic valve decreased from >70 mmHg to <20 mmHg after TAAVI. One-year survival ranged from 49.3% to 82% and the 3-year survival was 58% in 2 series. CONCLUSIONS: TAAVI appears to be feasible with a reasonable safety and efficacy portfolio. Randomised controlled trials are required to compare transapical vs. transfemoral TAVI when both techniques are equally feasible.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) through a transapical approach (TAAVI) for severe aortic stenosis becomes the procedure of choice in cases where patients have peripheral artery disease and unfeasible access due to excessive atherosclerotic disease of the iliofemoral vessels and aorta. The present systematic review aimed to assess the safety, success rate, clinical outcomes, hemodynamic outcomes, and survival benefits of TAAVI. METHODS: Electronic searches were performed in 6 databases from January 2000 to February 2012. The primary end points included feasibility and safety. Other end points included echocardiographic findings, functional class improvement, and survival. RESULTS: After applying the inclusion and exclusion criteria, 48 out of 154 shortlisted potentially relevant articles were selected for assessment. Of these, 26 studies from 24 centers including total number of 2,807 patients were included for appraisal and data extraction. The current evidence on TAAVI for aortic stenosis is limited to observational studies. Successful TAAVI implantation occurred in >90% of patients. On average, the procedure took between 64 to 154 minutes to complete. The incidence of major adverse events included 30-day mortality (4.7-20.8%); cerebrovascular accident (0-16.3%); major tachyarrhythmia (0-48.8%); bradyarrhythmia requiring permanent pacemaker insertion (0-18.7%); cardiac tamponade (0-11%); major bleeding (1-17%); myocardial infarction (0-6%); aortic dissection/rupture (0-5%); moderate to severe paravalvular leak (0.7-24%); cardiopulmonary bypass support (0-15%); conversion to surgery (0-9.5%); and valve-in-valve implantation (0.6-8%). Mean aortic valve area improved from 0.4-0.7 cm(2) before TAAVI to 1.4-2.1 cm(2) after TAAVI. The peak pressure gradient across the aortic valve decreased from >70 mmHg to <20 mmHg after TAAVI. One-year survival ranged from 49.3% to 82% and the 3-year survival was 58% in 2 series. CONCLUSIONS: TAAVI appears to be feasible with a reasonable safety and efficacy portfolio. Randomised controlled trials are required to compare transapical vs. transfemoral TAVI when both techniques are equally feasible.
Authors: Arnaud Van Linden; Jörg Kempfert; Ardawan J Rastan; David Holzhey; Johannes Blumenstein; Gerhard Schuler; Friedrich W Mohr; Thomas Walther Journal: Eur J Cardiothorac Surg Date: 2010-12-24 Impact factor: 4.191
Authors: Thomas Walther; Volkmar Falk; Michael A Borger; Todd Dewey; Gerhard Wimmer-Greinecker; Gerhard Schuler; Michael Mack; Friedrich W Mohr Journal: Eur J Cardiothorac Surg Date: 2006-11-09 Impact factor: 4.191
Authors: Peter Wenaweser; Thomas Pilgrim; Nadja Roth; Alexander Kadner; Stefan Stortecky; Bindu Kalesan; Fabienne Meuli; Lutz Büllesfeld; Ahmed A Khattab; Christoph Huber; Balthasar Eberle; Gabor Erdös; Bernhard Meier; Peter Jüni; Thierry Carrel; Stephan Windecker Journal: Am Heart J Date: 2011-05-11 Impact factor: 4.749
Authors: Martyn Thomas; Gerhard Schymik; Thomas Walther; Dominique Himbert; Thierry Lefèvre; Hendrik Treede; Holger Eggebrecht; Paolo Rubino; Iassen Michev; Rüdiger Lange; William N Anderson; Olaf Wendler Journal: Circulation Date: 2010-06-21 Impact factor: 29.690
Authors: Cosmo Godino; Francesco Maisano; Matteo Montorfano; Azeem Latib; Alaide Chieffo; Iassen Michev; Rasha Al-Lamee; Marta Bande; Marco Mussardo; Francesco Arioli; Alfonso Ielasi; Micaela Cioni; Maurizio Taramasso; Irina Arendar; Antonio Grimaldi; Pietro Spagnolo; Alberto Zangrillo; Giovanni La Canna; Ottavio Alfieri; Antonio Colombo Journal: JACC Cardiovasc Interv Date: 2010-11 Impact factor: 11.195
Authors: Rebecca T Hahn; Susheel Kodali; E Murat Tuzcu; Martin B Leon; Samir Kapadia; Deepika Gopal; Stamatios Lerakis; Brian R Lindman; Zuyue Wang; John Webb; Vinod H Thourani; Pamela S Douglas Journal: JACC Cardiovasc Imaging Date: 2015-03
Authors: Jayendrakumar S Patel; Amar Krishnaswamy; Lars G Svensson; E Murat Tuzcu; Stephanie Mick; Samir R Kapadia Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931